Skip to main content Accessibility help
×
Hostname: page-component-cd9895bd7-hc48f Total loading time: 0 Render date: 2024-12-28T13:21:48.641Z Has data issue: false hasContentIssue false

Debate 22A - Is there a Role for Immunotherapy in Ovarian Cancer?

Yes

from Section III - Ovarian Cancer

Published online by Cambridge University Press:  20 July 2023

Dennis S. Chi
Affiliation:
Memorial Sloan-Kettering Cancer Center, New York
Nisha Lakhi
Affiliation:
Richmond University Medical Center, Staten Island
Nicoletta Colombo
Affiliation:
University of Milan-Bicocca
Get access

Summary

The value of tertiary surgery in recurrent ovarian cancer is not well known due to the weak evidence we have, coming exclusively from retrospective series. Nevertheless, these retrospective studies have shown that achieving a complete cytoreduction at the time of the tertiary surgery improves patient overall survival compared with any residual tumor left. Unfortunately, there are not prospectively validated criteria predictive of complete cytoreduction; thus, patient selection is highly biased, and indiscriminate tertiary surgery outside of specialized centers should not be accepted.

Type
Chapter
Information
Publisher: Cambridge University Press
Print publication year: 2023

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Le Saux, O, et al. Challenges for immunotherapy for the treatment of platinum-resistant ovarian cancer. Seminars in Cancer Biology 2020.Google ScholarPubMed
Borella, F, et al. Immune checkpoint inhibitors in epithelial ovarian cancer: an overview on efficacy and future perspectives. Diagnostics (Basel) 2020;10(3):E146.CrossRefGoogle ScholarPubMed
Zamarin, D, et al. Randomized phase II trial of nivolumab versus nivolumab and ipilimumab for recurrent or persistent ovarian cancer: an NRG oncology study. J Clin Oncol 2020;38:18141823.CrossRefGoogle ScholarPubMed
Chmielewski, M, et al. TRUCKS, the fourth-generation CAR T cells: current developments and clinical translation. Adv Cell Gene Ther 2020;3:e84CrossRefGoogle Scholar
Parvathareddy, SK, et al. Differential expression of PD-L1 between primary and metastatic epithelial ovarian cancer and its clinico-pathological correlation. Sci Rep 2021;11:3750.CrossRefGoogle ScholarPubMed

Save book to Kindle

To save this book to your Kindle, first ensure no-reply@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

Available formats
×